| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | 
|---|---|---|---|---|---|---|
Income Statement  | ||||||
| Total Revenue | 1.51B | 1.47B | 1.30B | 1.22B | 1.17B | 1.10B | 
| Gross Profit | 1.16B | 168.00M | 167.62M | 76.83M | 115.61M | 201.16M | 
| EBITDA | 165.43M | 155.27M | 98.63M | 48.90M | 67.46M | 125.08M | 
| Net Income | 83.18M | 75.21M | 33.98M | 69.55M | 11.50M | 54.19M | 
Balance Sheet  | ||||||
| Total Assets | 777.83M | 719.79M | 672.73M | 781.58M | 900.32M | 963.13M | 
| Cash, Cash Equivalents and Short-Term Investments | 72.61M | 121.85M | 75.91M | 167.28M | 104.63M | 179.96M | 
| Total Debt | 284.12M | 292.49M | 334.52M | 383.97M | 536.85M | 564.60M | 
| Total Liabilities | 628.92M | 595.44M | 584.81M | 680.88M | 798.40M | 834.94M | 
| Stockholders Equity | 148.91M | 124.35M | 87.92M | 100.70M | 101.92M | 128.19M | 
Cash Flow  | ||||||
| Free Cash Flow | 78.93M | 101.69M | -106.13M | -2.76M | -6.10M | 88.17M | 
| Operating Cash Flow | 131.43M | 143.64M | 23.28M | 98.87M | 59.08M | 121.27M | 
| Investing Cash Flow | -105.66M | -9.11M | -84.45M | 155.64M | -59.39M | 2.00M | 
| Financing Cash Flow | -89.56M | -87.87M | -30.93M | -191.86M | -74.84M | -38.16M | 
Name  | Overall Rating  | Market Cap  | P/E Ratio  | ROE  | Dividend Yield  | Revenue Growth  | EPS Growth  | 
|---|---|---|---|---|---|---|---|
| ― | C$1.36B | 16.46 | 65.09% | 3.19% | 8.68% | 39.93% | |
| ― | C$267.45M | 2.12 | 41.13% | 2.49% | -35.35% | 948.72% | |
| ― | C$1.82B | 49.45 | 6.94% | 4.89% | 10.13% | 1.30% | |
| ― | C$223.39M | ― | -2.17% | 0.56% | -0.16% | 75.25% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | C$1.26B | ― | -14.61% | ― | 20.36% | -186.10% | 
Extendicare Inc. announced a cash dividend of C$0.042 per common share for October 2025, payable on November 17, 2025, to shareholders of record as of October 31, 2025. This announcement reflects Extendicare’s ongoing commitment to providing shareholder value and maintaining its position as a key player in the senior care industry in Canada.
The most recent analyst rating on (TSE:EXE) stock is a Buy with a C$18.00 price target. To see the full list of analyst forecasts on Extendicare stock, see the TSE:EXE Stock Forecast page.
Extendicare Inc. has announced the release of its third-quarter financial results for 2025, scheduled for November 11, with a subsequent conference call on November 12. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic positioning in the senior care industry, potentially impacting investor decisions and market perceptions.
The most recent analyst rating on (TSE:EXE) stock is a Buy with a C$18.00 price target. To see the full list of analyst forecasts on Extendicare stock, see the TSE:EXE Stock Forecast page.
Extendicare Inc. has announced a cash dividend of C$0.042 per common share for September 2025, payable on October 15, 2025, to shareholders on record as of September 30, 2025. This announcement reflects the company’s ongoing commitment to providing value to its shareholders and maintaining its position as a key player in the senior care industry in Canada.
The most recent analyst rating on (TSE:EXE) stock is a Hold with a C$14.50 price target. To see the full list of analyst forecasts on Extendicare stock, see the TSE:EXE Stock Forecast page.
Extendicare Inc. recently held its earnings call, revealing a generally positive sentiment despite some challenges. The company reported strong growth in key areas like Adjusted EBITDA and home health care volumes, alongside successful acquisitions. However, it faced hurdles with revenue losses from closed Class C homes and a decline in Managed Services revenue. Overall, the positive developments and strategic acquisitions suggest a robust position for future growth.
Extendicare Inc. reported a 15.4% increase in adjusted EBITDA for Q2 2025, driven by growth in its home health care segment and improvements in long-term care, including the acquisition of nine Class C LTC homes. The company completed several strategic transactions, including the sale of three LTC projects and the acquisition of Closing the Gap, which is expected to enhance its service offerings and operational scale. These moves, along with increased credit facilities, position Extendicare for future growth and improved market positioning.
The most recent analyst rating on (TSE:EXE) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on Extendicare stock, see the TSE:EXE Stock Forecast page.